Certified by Founder Lodge
OrbiMed
United States - New York, NY
INVESTOR
1 Disclosed Funding Rounds $261,000,000
52 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit f
Company | Date | Round | Raised |
---|---|---|---|
CHARM Therapeutics | June, 09 ,2022 | Series A | $50,000,000 |
Treeline Biosciences | October, 18 ,2022 | Series A | $261,000,000 |
Congruence Therapeutics | March, 07 ,2023 | Series A | $65,000,000 |
Delfi Diagnostics | July, 18 ,2022 | Series B | $225,000,000 |
Aer Therapeutics, Inc. | April, 17 ,2023 | Series A | $36,000,000 |
Pathalys Pharma | February, 07 ,2023 | Unknown | $150,000,000 |
Convergent Therapeutics, Inc. | May, 04 ,2023 | Series A | $90,000,000 |
CHARM Therapeutics | June, 09 ,2022 | Series A | $50,000,000 |
ADARx Pharmaceuticals Inc. | August, 10 ,2023 | Series C | $200,000,000 |
Congruence Therapeutics | March, 07 ,2023 | Series A | $65,000,000 |
Fore Biotherapeutics | August, 25 ,2023 | Series D | $75,000,000 |
Aer Therapeutics, Inc. | April, 17 ,2023 | Series A | $36,000,000 |
Epigenic Therapeutics | August, 30 ,2023 | Series A | $32,000,000 |
Convergent Therapeutics, Inc. | May, 04 ,2023 | Series A | $90,000,000 |
Star Therapeutics | September, 05 ,2023 | Series C | $90,000,000 |
ADARx Pharmaceuticals Inc. | August, 10 ,2023 | Series C | $200,000,000 |
Corteria Pharmaceuticals | September, 07 ,2023 | Series A | $69,471,000 |
Fore Biotherapeutics | August, 25 ,2023 | Series D | $75,000,000 |
ReCode Therapeutics | September, 20 ,2023 | Series B | $50,000,000 |
Epigenic Therapeutics | August, 30 ,2023 | Series A | $32,000,000 |
Adela, Inc. | September, 26 ,2023 | Unknown | $48,000,000 |
Star Therapeutics | September, 05 ,2023 | Series C | $90,000,000 |
Evozyne | September, 28 ,2023 | Series B | $81,000,000 |
Corteria Pharmaceuticals | September, 07 ,2023 | Series A | $69,471,000 |
Iambic Therapeutics | October, 06 ,2023 | Series B | $100,000,000 |
ReCode Therapeutics | September, 20 ,2023 | Series B | $50,000,000 |
Rampart Bioscience | October, 25 ,2023 | Series A | $85,000,000 |
Adela, Inc. | September, 26 ,2023 | Unknown | $48,000,000 |
Triveni Bio | October, 27 ,2023 | Series A | $92,000,000 |
Evozyne | September, 28 ,2023 | Series B | $81,000,000 |
Forward Therapeutics, Inc. | November, 09 ,2023 | Series A | $50,000,000 |
Iambic Therapeutics | October, 06 ,2023 | Series B | $100,000,000 |
Koya Medical, Inc. | November, 16 ,2023 | Unknown | $30,000,000 |
Rampart Bioscience | October, 25 ,2023 | Series A | $85,000,000 |
Odyssey Therapeutics | December, 06 ,2023 | Series C | $101,000,000 |
Triveni Bio | October, 27 ,2023 | Series A | $92,000,000 |
Noctrix Health, Inc. | January, 17 ,2024 | Series C | $40,000,000 |
Forward Therapeutics, Inc. | November, 09 ,2023 | Series A | $50,000,000 |
Sionna Therapeutics | March, 07 ,2024 | Series C | $182,000,000 |
Koya Medical, Inc. | November, 16 ,2023 | Unknown | $30,000,000 |
Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
Odyssey Therapeutics | December, 06 ,2023 | Series C | $101,000,000 |
Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
Noctrix Health, Inc. | January, 17 ,2024 | Series C | $40,000,000 |
Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
Sionna Therapeutics | March, 07 ,2024 | Series C | $182,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Candid Therapeutics | September, 10 ,2024 | Unknown | $370,000,000 |